Recombinant Human Transmembrane protein 65 (TMEM65), partial

What is the basic structure of recombinant human TMEM65 (partial)?

Recombinant Human TMEM65 protein (partial) typically consists of a fragment in the 63 to 240 amino acid range of the full-length protein. The protein contains three transmembrane domains with a characteristic amino acid sequence: MEALNTA QGARDFI YSLHSTE RSCLLKE LHRFESI AIAQEKL EAPPPTPGQLRY VFIHNAI PFIGFGF LDNAIMI VAGTHIE MSIGII LGISTAAAAALGN LVSDLAGLGLAGY VEALASRLGLSIPDLTPKQ VDMWQTRLSTHLG KAVGVTIGCILGM FPLIFYGGGEEEK LETKS . When expressed in Escherichia coli with a His-tag, the recombinant protein typically achieves >85% purity and is suitable for SDS-PAGE analysis and various experimental applications .

How does the partial recombinant TMEM65 compare structurally to the native full-length protein?

The partial recombinant TMEM65 (typically aa 63-240) contains the core transmembrane domains but lacks the N-terminal mitochondrial targeting sequence and some C-terminal regions found in the native protein. When examining structural and functional studies, researchers should consider that:

• The full-length mature mitochondrial TMEM65 contains a soluble N-terminal 'matrix hook domain' that interacts with both the soluble 'regulatory loop' of NCLX and the C-terminal end of NCLX's longest transmembrane helix .

• In silico structural modeling using AlphaFold predicted structures indicates that the three individual transmembrane domains of TMEM65 align within a specific cleft next to the longest transmembrane helix of NCLX .

• When working with the partial protein, researchers should account for potential differences in protein-protein interactions that might depend on regions absent in the recombinant version.

Table 1. Comparison between Full-length and Partial Recombinant TMEM65

What are the primary cellular functions of TMEM65?

TMEM65 demonstrates diverse functional roles in different cellular compartments, particularly in cardiac tissue and mitochondria:

• Cardiac function: TMEM65 is essential for maintaining proper cardiac intercalated disk (ICD) structure and function, as well as cardiac conduction velocity in the heart. Its association with SCN1B is required for stabilizing the perinexus in the ICD and for localization of GJA1 (Connexin 43) and SCN5A to the ICD .

• Gap junction regulation: TMEM65 regulates the function of the gap junction protein GJA1 and contributes to its stability and proper localization to cardiac intercalated disks, thereby regulating gap junction communication .

• Mitochondrial function: TMEM65 plays a critical role in regulating mitochondrial respiration and mitochondrial DNA copy number maintenance .

• Calcium homeostasis: TMEM65 is required for Na⁺-dependent mitochondrial Ca²⁺ efflux through regulation of NCLX (mitochondrial sodium-calcium exchanger). Loss of TMEM65 function disrupts this process, causing pathogenic mitochondrial Ca²⁺ overload, cell death, and organ-level dysfunction .

• Cell survival: TMEM65 deletion causes excessive mitochondrial permeability transition, whereas TMEM65 overexpression protects against necrotic cell death during cellular Ca²⁺ stress .

How does TMEM65 regulate mitochondrial calcium efflux at the molecular level?

TMEM65 regulates mitochondrial calcium (Ca²⁺) efflux through its interaction with the mitochondrial sodium-calcium exchanger (NCLX). The molecular mechanism involves several key processes:

• Physical interaction: In silico structural modeling using predicted AlphaFold structures of human TMEM65 and NCLX reveals that TMEM65's three transmembrane domains align within a specific cleft adjacent to NCLX's longest transmembrane helix .

• Functional positioning: The soluble N-terminal 'matrix hook domain' of TMEM65 interacts with both the soluble 'regulatory loop' of NCLX and the C-terminal end of NCLX's longest transmembrane helix .

• Na⁺-dependent mechanism: TMEM65 is specifically required for Na⁺-dependent mitochondrial Ca²⁺ efflux, as demonstrated by loss-of-function studies .

• Protection against permeability transition: TMEM65 prevents excessive mitochondrial permeability transition during calcium stress, with overexpression providing protection against necrotic cell death .

• Homeostatic regulation: The interaction between TMEM65 and NCLX maintains proper calcium homeostasis, preventing pathogenic mitochondrial Ca²⁺ overload that can lead to cell death and organ dysfunction .

What are the optimal expression systems for producing functional recombinant TMEM65?

For optimal expression of recombinant TMEM65, research data indicates several effective approaches:

• E. coli expression system: The partial human TMEM65 protein (aa 63-240) has been successfully expressed in E. coli with >85% purity . This system is particularly suitable for producing the partial protein for structural and biochemical studies.

• Vector selection: The pCMV6-XL4 vector has been used for TMEM65 expression, with ampicillin (100 μg/mL) as the selection marker for E. coli transformation .

• Expression optimization considerations:

  • Codon optimization may be necessary for efficient expression in prokaryotic systems

  • Expression of the full-length protein may require eukaryotic systems due to post-translational modifications

  • Addition of affinity tags (such as His-tag) facilitates purification while maintaining functionality

• Quality control parameters:

  • Verify sequence integrity before expression

  • Confirm protein purity (>85%) through SDS-PAGE

  • Validate protein functionality through specific activity assays

  • Assess proper folding through circular dichroism or limited proteolysis

What experimental approaches are most effective for studying TMEM65's role in mitochondrial calcium efflux?

To investigate TMEM65's role in mitochondrial calcium efflux, researchers should consider these methodological approaches:

• Loss-of-function studies:

  • siRNA-mediated knockdown of TMEM65 (VNP-encapsulated TMEM65-siRNA has shown efficacy)

  • CRISPR-Cas9 gene editing to create TMEM65-knockout cell lines

  • Measure Na⁺-dependent mitochondrial Ca²⁺ efflux rates before and after TMEM65 depletion

• Gain-of-function approaches:

  • Overexpression of TMEM65 in appropriate cell models

  • Assessment of protection against necrotic cell death during cellular Ca²⁺ stress

  • Quantification of mitochondrial permeability transition susceptibility

• Interaction analysis techniques:

  • Co-immunoprecipitation assays to verify TMEM65-NCLX interaction

  • Proximity ligation assays to confirm protein-protein interactions in situ

  • Co-fractionation studies combined with structural modeling

• Calcium dynamics measurement:

  • Real-time fluorescent calcium indicators for living cells

  • Patch-clamp electrophysiology of mitochondrial membranes

  • Measurement of mitochondrial membrane potential during calcium flux

• In vivo validation:

  • Tissue-specific knockout models to assess organ-level dysfunction

  • Cardiac conduction studies in animal models with modified TMEM65 expression

How is TMEM65 involved in cancer progression, particularly in gastric cancer?

TMEM65 has emerged as a significant factor in gastric cancer (GC) progression through several mechanisms:

• Genomic amplification: TMEM65 amplification has been identified through genomic hybridization microarray profiling of copy-number variations in gastric cancer .

• Expression patterns: TMEM65 mRNA levels are significantly upregulated in gastric cancer compared to adjacent normal tissues, with expression positively associated with TMEM65 amplification .

• Prognostic significance: High TMEM65 expression or DNA copy number predicts poor prognosis in gastric cancer patients. Those with TMEM65 amplification (n=129) or overexpression (n=78) show significantly shortened survival .

• Molecular mechanisms:

  • TMEM65 promotes cell proliferation, cell cycle progression, and cell migration/invasion abilities

  • It inhibits apoptosis in cancer cells

  • TMEM65 exerts oncogenic effects through activating the PI3K-Akt-mTOR signaling pathway, increasing expression of key regulators (p-Akt, p-GSK-3β, p-mTOR)

• Downstream effectors: YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase) was identified as a direct downstream effector of TMEM65. Direct binding of TMEM65 with YWHAZ in the cytoplasm inhibits ubiquitin-mediated degradation of YWHAZ .

What therapeutic strategies targeting TMEM65 show promise in disease models?

Research indicates several promising therapeutic approaches targeting TMEM65:

• siRNA-mediated silencing: TMEM65 depletion by VNP-encapsulated TMEM65-siRNA significantly suppressed tumor growth in subcutaneous xenograft models of gastric cancer .

• Inhibition of oncogenic pathways: Since TMEM65 activates the PI3K-Akt-mTOR signaling pathway in cancer, combination therapy with established inhibitors of this pathway might enhance anti-tumor effects .

• Mitochondrial calcium homeostasis modulation: Manipulating TMEM65 function could serve as a novel strategy for therapeutic control of mitochondrial Ca²⁺ homeostasis in conditions characterized by calcium dysregulation .

• YWHAZ targeting: Since TMEM65's oncogenic effect is partly dependent on YWHAZ, strategies disrupting their interaction could have therapeutic potential in cancers overexpressing TMEM65 .

• Biomarker applications: TMEM65 overexpression may serve as an independent new biomarker in gastric cancer, potentially guiding personalized treatment approaches .

Table 2. Therapeutic Approaches Targeting TMEM65 in Disease Models

How can structural studies of TMEM65-NCLX interactions guide functional investigations?

Structural studies of TMEM65-NCLX interactions provide critical insights that can guide functional investigations through several approaches:

• In silico modeling applications:

  • AlphaFold predicted structures of human TMEM65 and NCLX have been used to interrogate potential physical interactions

  • Modeling of interactions between each individual TMEM65 transmembrane domain with NCLX yielded a consensus model where each domain aligned within the same cleft next to NCLX's longest transmembrane helix

  • These models can guide site-directed mutagenesis experiments to verify interaction hotspots

• Domain-specific interaction analysis:

  • The soluble N-terminal 'matrix hook domain' of TMEM65 interacts with both the soluble 'regulatory loop' of NCLX and the C-terminal end of NCLX's longest transmembrane helix

  • Structure-guided truncation experiments can define minimal domains required for functional interaction

• Structure-based drug design opportunities:

  • Identified interaction interfaces can serve as targets for small molecule modifiers

  • Virtual screening campaigns targeting the TMEM65-NCLX interface may identify potential therapeutic compounds

  • Peptide mimetics based on interaction domains could serve as specific modulators

• Functional validation approaches:

  • Structure-guided mutations can be introduced to disrupt specific interactions

  • Calcium flux assays can measure the functional consequences of these targeted mutations

  • Correlation between structural alterations and functional outcomes can establish structure-function relationships

What are the challenges in integrating TMEM65's diverse functions in cardiac tissue and mitochondria?

Integrating TMEM65's diverse functions in cardiac tissue and mitochondria presents several research challenges:

• Subcellular localization complexities:

  • TMEM65 functions both at cardiac intercalated disks and in mitochondria

  • Determining how trafficking to different compartments is regulated requires sophisticated imaging approaches

  • Potential for different isoforms or post-translational modifications directing localization

• Methodological approach integration:

  • Cardiac function studies typically involve tissue-level electrophysiology

  • Mitochondrial studies focus on isolated organelles or cellular bioenergetics

  • Integrating these different experimental scales requires careful experimental design

• Tissue-specific effects vs. universal functions:

  • Distinguishing between cardiac-specific roles (gap junction regulation) and more universal mitochondrial functions (calcium homeostasis)

  • Differential expression and function across tissues must be systematically investigated

  • Different disease contexts may activate distinct functional pathways

• Temporal dynamics:

  • Acute vs. chronic alterations in TMEM65 expression may have different consequences

  • Developmental timing of TMEM65 function in cardiac development vs. adult physiology

  • Adaptive responses to TMEM65 manipulation may confound interpretations

• Therapeutic targeting considerations:

  • Interventions targeting one function may have unintended consequences on other functions

  • Tissue-specific delivery systems may be required for therapeutic applications

  • Biomarker development needs to account for context-dependent functions

How should researchers interpret conflicting data regarding TMEM65 function across different experimental systems?

When encountering conflicting data regarding TMEM65 function, researchers should implement a systematic approach to interpretation:

• System-specific considerations:

  • Cell type differences: TMEM65 may function differently in cardiac cells vs. cancer cells vs. other cell types

  • Expression level variations: Endogenous vs. overexpression systems may yield different results

  • Subcellular localization: TMEM65 distribution may vary between experimental systems

• Methodology-dependent factors:

  • Acute vs. chronic manipulation: siRNA knockdown vs. stable knockout models

  • In vitro vs. in vivo studies: Cell culture findings may not translate to animal models

  • Recombinant protein limitations: Partial protein studies may miss important functions

• Reconciliation strategies:

  • Direct comparison studies under identical conditions

  • Meta-analysis of multiple datasets with statistical evaluation

  • Collaboration between labs reporting conflicting results

• Validation approaches:

  • Multiple technical approaches to address the same question

  • Independent replication in different laboratory settings

  • Cross-validation with emerging literature findings

What bioinformatic approaches are most effective for analyzing TMEM65's interaction networks?

For comprehensive analysis of TMEM65's interaction networks, researchers should consider these bioinformatic approaches:

• Protein-protein interaction prediction:

  • AlphaFold-based structural modeling has successfully predicted TMEM65-NCLX interactions

  • Docking simulations can identify potential binding partners

  • Co-expression network analysis can reveal functional associations

• Pathway enrichment analysis:

  • TMEM65 has been linked to PI3K-Akt-mTOR signaling in cancer contexts

  • Gene set enrichment analysis following TMEM65 manipulation can identify regulated pathways

  • Hierarchical clustering of differentially expressed genes can reveal functional modules

• Multi-omics data integration:

  • Combining proteomic, transcriptomic, and epigenomic data

  • Correlation of TMEM65 expression with genome-wide datasets

  • Network medicine approaches to identify disease associations

• Evolutionary analysis:

  • Conservation patterns of TMEM65 across species can indicate functional domains

  • Comparative genomics approaches to identify co-evolved proteins

  • Phylogenetic profiling to predict functional partners

Table 3. Bioinformatic Resources for TMEM65 Research